NPSC is part of the Phenomics Phenomenon

on .

Biocentury, a leading provider of value-added information, analysis and data for the biotech and pharma industries, has just published and article highlighting a comeback of phenotypic screening in drug discovery, deemed the "Phenomics Phenomenon", ....and NPSC is a part of it!

In the article Michael Leviten interviewed industry leaders from Johnson and Johnson, Novartis, Perlara, Recursion Pharmaceuticals, Servier, Teleos, and Vertex Pharmaceuticals, who expressed thier opinion that the current prefered approach in early drug discovery that combines genetic screens with traget-based approaches, is not delivering enough results in the clinic. 

Michael also interviewed leaders from academia, including our COO Dr Paul Andrews, who are adopting the new technologies that enable phenotypic screening to be fit for translating novel biology into drug discovery. Paul exposed the main reasons for the adoption of phenotypic screening in drug discovery, which includes physiological relevance of the assays, and higher sucess rates in translation to the clinic.  New phenomics technologies, which are available at the NPSC, allow complex models of human disease, such as iPS cells, co-cultures, organoids and patient tissue, to be screened against large compound libraries at the same time as multiparapetric data is measured (more than a 1,000 data points can be measured simulateously). This means that phenotipyc screening is now, more than ever, relevant to modern drug discovery.

Link to Biocentury article by Michael Leviten


NPSC is a facility run and operated by the Universities of Dundee, Edinburgh and Oxford, which are registered UK-based charities. 

Copyright © 2016.